Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data

Conclusions:
Perampanel was well tolerated and improved seizure control in 42% of patients (50– 100% reduction), with higher rates in those not receiving a concomitant enzyme inducer. AEs, particularly dizziness, were common but often disappeared with a slight dose reduction. The results are consistent with those from randomized controlled trials.

Source: Therapeutic Advances in Neurological Disorders - October 12, 2016 Category: Neurology Authors: Rohracher, A., Kalss, G., Leitinger, M., Granbichler, C., Deak, I., Dobesberger, J., Kuchukhidze, G., Thomschewski, A., Höfler, J., Trinka, E. Tags: Original Research Source Type: research